London: The marketplace for weight problems therapies throughout the seven main markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is projected to develop from $2.43 billion in 2021 to $37.1 billion in 2031, pushed by the launch of therapies with promising efficacies and/or new routes of administration, in addition to the expansion of the overweight inhabitants, forecasts GlobalData.
In response to GlobalData, the expansion can be supported by the launch of Novo Nordisk’s Wegovy (semaglutide) throughout the 5EU (France, Germany Italy, Spain, and the UK), coupled with the anticipated launch of Eli Lilly’s tirzepatide throughout the 7MM, together with the awaited approval of one other glucagon-like peptide-1 receptor agonist (GLP-1RA) pipeline therapies, and the introduction of therapies with new mechanisms of motion to the weight problems area throughout the forecast interval.
GlobalData’s newest report, ‘Weight problems: Seven-Market Drug Forecast and Market Evaluation,’ reveals that GLP-1RA therapies will proceed to stay the dominant therapy modality for DME throughout the forecast interval. This theme is noticed each within the presently marketed merchandise in addition to within the late-stage pipeline merchandise, with firms specializing in enhancing efficacy with these therapies.
Sara Reci, Healthcare Analyst, GlobalData, commented, “Novo Nordisk’s Wegovy has established the efficacy of GLP-1RA therapies for weight problems. Nevertheless, the necessity for extra efficacious therapies that concurrently assist preserve weight reduction stays of utmost curiosity, in line with the interviewed key opinion leaders (KOLs), who acknowledge that weight problems is a continual illness and thus upon therapy cessation, sufferers usually regain all the burden they misplaced whereas on therapy. That is due to this fact a urgent situation within the overweight affected person inhabitants.”
Wanting forward, lots of the present late-stage pipeline merchandise for weight problems emulate what’s presently in the marketplace, using the GLP-1RA mechanism of motion. Concurrently, double- and triple-agonist mechanisms are a dominant development within the weight problems pipeline.
One such instance is Eli Lilly’s tirzepatide, whose mechanism of motion entails GLP-1R and GIPR agonism. GlobalData forecasts that extremely anticipated tirzepatide will seize vital market share from different GLP-1RA therapies, together with Novo Nordisk’s Wegovy, upon its launch, because of its promising efficacy in medical trials. Different examples embody Novo Nordisk’s CagriSema, which employs GLP-1R and amylin analogue agonism, and Eli Lilly’s orforglipron, which is predicted to be the primary triple-agonist remedy within the weight problems area.
Whereas the weight problems market is projected to develop strongly within the forecast interval, the potential obstacles to this development embody patent expiries inside the forecast interval. For instance, Saxenda and Victoza’s (liraglutide) patents are set to run out within the US and 5EU in 2023; in Japan, Victoza’s patent expired in 2022, resulting in the anticipated entry of biosimilars.
Reci concluded, “Liraglutide biosimilars are additionally set to enter the weight problems market throughout the forecast interval, which can undoubtedly compete with their mother or father medication, Saxenda and Victoza. Nevertheless, the launch of tirzepatide and different late-stage pipeline therapies with superior efficacies, new mechanisms of motion, a few of which entail double- and triple-agonism, in addition to new routes of administration are undoubtedly a driving power for the market development within the weight problems area.”
